HRS 22: Complications Among S-ICD Vs TV-ICD Recipients: The ATLAS Trial | Dr Jeff Healey

Watch on Radcliffe Cardiology: www.radcliffecardiology.com/v...
In this short interview, Dr Jeff Healey (McMaster University, Hamilton, CA) talks about the key data from the ATLAS (Avoid Transvenous Leads in Appropriate Subjects) trial (NCT02881255).
The aim of the study was to compare standard, single chamber transvenous ICD (TV-ICD) to sub-cutaneous ICD (S-ICD)(Boston Scientific EMBLEM) in occurrence of perioperative and long term device related complications and failed appropriate clinical shocks and arrhythmic death.
Discussion Points:
1. Trial Background
2. Study Design & Eligibility Criteria
3. Key Findings
4. When to Select S-ICD Over TV-ICD
5. Implications for Practice & for Guidelines
6. Next Steps
Recorded on-site at Heart Rhythm 2022, San Francisco.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.